Advertisement
Canada markets closed
  • S&P/TSX

    21,728.55
    +14.01 (+0.06%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • CAD/USD

    0.7281
    +0.0020 (+0.28%)
     
  • CRUDE OIL

    79.13
    -2.80 (-3.42%)
     
  • Bitcoin CAD

    79,273.27
    -3,360.10 (-4.07%)
     
  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     
  • GOLD FUTURES

    2,330.20
    +27.30 (+1.19%)
     
  • RUSSELL 2000

    1,980.23
    +6.32 (+0.32%)
     
  • 10-Yr Bond

    4.5950
    -0.0910 (-1.94%)
     
  • NASDAQ futures

    17,474.75
    -96.50 (-0.55%)
     
  • VOLATILITY

    15.39
    -0.26 (-1.66%)
     
  • FTSE

    8,121.24
    -22.89 (-0.28%)
     
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • CAD/EUR

    0.6796
    -0.0006 (-0.09%)
     

Why Dynavax Crushed the Market on Thursday

Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. Thursday morning, Valneva announced that the committee for medicinal products for human use (CHMP) advising the European Medicines Agency (EMA) has recommended the jab be granted marketing authorization as a primary shot for adults 18 to 50 years old. The next step is for the European Commission (EC) to review the CHMP's recommendation and make a decision.